BioXcel Therapeutics Highlights Urgent Need for Alzheimer’s Agitation Solutions

BioXcel Therapeutics (NASDAQ:BTAI) recently convened a virtual roundtable featuring key opinion leaders to discuss the significant unmet need in managing acute agitation episodes in Alzheimer’s dementia. Participants underscored the absence of FDA-approved treatments specifically designed for these acute episodes, emphasizing the challenges faced by patients, caregivers, and healthcare providers.

During the event, CEO Vimal Mehta reiterated the company’s commitment to developing BXCL501, a novel treatment aimed at addressing this pressing issue. Mehta referred to findings from a previously announced Phase III pivotal study, which indicated that BXCL501 was well-tolerated and successfully met its primary efficacy endpoint in treating agitation linked to Alzheimer’s dementia.

Understanding Acute Agitation in Alzheimer’s Patients

Clinicians participating in the roundtable characterized acute agitation as a frequent and distinct challenge in Alzheimer’s care. Dr. David Grossberg highlighted that diagnostic criteria established by the International Psychogeriatric Association focus primarily on persistent agitation lasting two weeks or longer, neglecting the intermittent acute episodes that can significantly disrupt patient stability. He pointed out that acute agitation often leads to increased healthcare resource utilization, including unnecessary transfers to emergency rooms.

Dr. Mary Sanford, who works in nursing home settings, noted that clinicians frequently resort to “last resort” medications during acute episodes, which may not be suitable for older adults. She described the situation as a “very chronic problem with acute flares,” stating that this cycle severely impacts the quality of life for both patients and their caregivers.

Dr. Richard Porsteinsson added that episodic agitation can manifest across various care environments, including long-term care facilities and at home. He explained that even patients receiving treatment for chronic agitation can experience breakthrough episodes, triggered by confusion, pain, or difficulty in communicating discomfort.

Current Treatment Landscape and BXCL501’s Potential

The discussion repeatedly returned to the lack of effective FDA-approved treatments tailored for acute agitation. Dr. Grossberg noted that clinicians often turn to off-label medications, such as antipsychotics like quetiapine and olanzapine, in hospital environments. These options, while sometimes effective, carry risks including sedation and increased fall hazards, complicating patient assessments.

Porsteinsson emphasized the necessity of a treatment that offers rapid onset without excessive sedation. He explained that many sedating medications can lead to prolonged drowsiness, raising concerns regarding their use in older patients. Additionally, antipsychotics typically carry warnings about increased mortality, which can dissuade prescribers from using them in specific contexts.

BXCL501, an oral thin-film formulation of dexmedetomidine, was presented as a potential solution. This formulation allows for absorption via the oral mucosa, making it accessible even for patients with moderate to advanced dementia. Porsteinsson expressed optimism about its applicability but cautioned that a “100% success rate” cannot be guaranteed.

The panelists discussed the feasibility of self-administration during agitation episodes. Dr. Grossberg acknowledged that self-medication is generally unlikely in Alzheimer’s patients, as caregivers typically identify agitation and make treatment decisions. Yet, Porsteinsson observed that patients in distress might still accept assistance.

On the subject of efficacy timing, Porsteinsson indicated that noticeable improvements could occur within approximately 30 minutes, with a clearer distinction between drug and placebo effects observable at around 60 minutes. He characterized the most intense agitation episodes as rare, contrasting them with more frequent mid-level episodes where non-pharmacological strategies may fall short.

Safety considerations were also addressed, with Porsteinsson referencing side effects noted in the TRANQUILITY II study, which included mild somnolence and slight decreases in blood pressure. He described lethargy as a rare outcome, mentioning the established use of dexmedetomidine in ICU settings as a reassuring factor for its safety profile.

Panelists explored the potential for BXCL501 to be used alongside chronic agitation therapies. Dr. Grossberg expressed confidence that utilizing the oral film for breakthrough agitation could be compatible with existing treatments like brexpiprazole, although he acknowledged it had not been specifically studied in this context.

In concluding remarks, Sanford articulated the potential benefits of having an on-demand treatment option that could assist caregivers in managing patients at home, thereby delaying the need for institutionalization. Porsteinsson emphasized the desire for a treatment with reliable absorption and predictable effects, particularly for episodic events that disrupt daily activities.

Mehta concluded the roundtable by thanking participants and reaffirming BioXcel Therapeutics’ commitment to addressing the significant gap in treatments for sudden episodic agitation in Alzheimer’s dementia. He emphasized that advancing solutions tailored to these acute episodes remains a top priority for the company.

BioXcel Therapeutics, Inc. is a biopharmaceutical firm dedicated to leveraging an AI-driven drug development platform to identify and advance innovative therapies in neuroscience and immunology. Their commercial portfolio includes two FDA-approved therapies, including IGALMI® (dexmedetomidine), which is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.